No Data
No Data
De Motu Cordis (DMC) Announces Plans for the Next Stage of Development for DMC-IH1, an Inhaled Epinephrine Drug Device Combination Product
BRISBANE, Australia, July 17, 2024 /PRNewswire/ -- De Motu Cordis (DMC) today announced plans for the next stage of development with its Contract Development and Manufacturing Organization (CDMO)
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent, Inc. (CTLT) announced that it has completed the expansion of its clinical supply facility in Schorndorf, Germany.
Catalent Completes $25 Million Expansion of Its Clinical Supply Facility in Schorndorf, Germany
Expansion adds more temperature-controlled storage and dedicated space for FastChain demand-led supply service Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments
Catalent Price Target Maintained With a $63.50/Share by RBC Capital
Catalent Price Target Maintained With a $63.50/Share by RBC
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.
RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
RBC Capital analyst Sean Dodge maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 39.3% and a